DaltonTx
- Company typePrivate
- Founded2025
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
DaltonTx firmographics
Firmographics- Name
- DaltonTx
- Legal name
- DaltonTx Limited
- Website
- https://daltontx.com
- Company type
- Private
- Founded year
- 2025
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
DaltonTx industry classification
Industry- Product category
- AI Drug Discovery Platform
- NAICS
- Software Publishers (5132)
- SIC
- Services-Computer Integrated Systems Design (7373)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
Keywords
Where DaltonTx is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
DaltonTx business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations
Revenue model
- Platform Subscription/ Licensing: Enterprise licensing of the Dalton platform to pharma, biotech, and CROs for AI-enabled drug discovery capabilities. The platform is offered as infrastructure that organisations can integrate into their existing workflows, suggesting a subscription or licensing model.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
DaltonTx product offering
Product offeringCore offering
DaltonTx offers the Dalton platform, an AI-powered drug discovery system that integrates agentic AI, human expertise, and experimental data into a continuous learning engine for small molecules and biologics. The platform covers the full discovery lifecycle including data ingestion, model training, molecule generation, synthesis planning, and experiment prioritisation. It links molecules, assays, models, experimental outcomes, project context, and human decisions into a single learning system that captures organisational memory across programmes.
Product overview
DaltonTx offers a single unified product platform called Dalton — an AI-enabled drug discovery platform that integrates agentic AI, human expertise, and experimental data into a continuous learning engine. The platform is purpose-built for both small molecules and biologics, covering the full discovery lifecycle including data ingestion, model training, molecule generation, synthesis planning, and experiment prioritisation. The platform links molecules, assays, models, experimental outcomes, project context, and human decisions into a single learning system that captures organisational memory over time, helping teams understand what worked, what failed, and why. Scientists interact with the system through conversational workflows, combining their expertise with an engine that iterates and learns.
Differentiator
Problem solved
Functional benefit
Products and services
- Dalton platform AI-powered drug discovery platform that integrates agentic AI, human expertise, and experimental data into a continuous learning engine for small molecules and biologics. Covers the full discovery lifecycle including data ingestion, model training, molecule generation, synthesis planning, and experiment prioritisation, and is offered to pharma, biotech, and CRO customers as enterprise-integrated infrastructure.
Quantifiable outcome
- Retrospective evaluation shows potential for more efficient candidate selection and reduced synthesis burden on legacy oncology programme
Companies that use DaltonTx
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
DaltonTx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability7 records
Feature5 records
DaltonTx partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- Sygnature DiscoverycoreStrategic collaboration with leading integrated drug discovery CRO. DaltonTx's platform incorporated into Sygnature Discovery's computational and medicinal chemistry toolkit alongside existing tools including SygDesign, BullFrog AI, and Iktos. Sygnature Discovery is conducting retrospective evaluation of a legacy oncology programme with a Phase I clinical candidate to assess platform's impact on candidate selection efficiency.
- Bonito BiosciencescoreCollaboration to advance precision delivery systems for oligotherapeutic medicines, initially focusing on CNS delivery. Combines Bonito's giga-scale encoded ligand libraries and functional cellular selection platform with DaltonTx's adaptive AI for iterative modelling, prediction, and optimization of delivery ligands. Companies aim to establish iterative learning loop for discovering delivery systems for tissues historically inaccessible to oligotherapeutics.
- Oxford University InnovationminorTechnology transfer and support organisation for University of Oxford, providing support to DaltonTx as the company was founded on technology developed at Oxford.
Scale indicators2 records
Recent moves6 records
Expansion highlights6 records
DaltonTx competitors and assessment
Company assessmentDirect peers
- Iktos: Generative AI platform for small molecule drug discovery. Coexists with DaltonTx in Sygnature Discovery's toolkit, making it a directly comparable competitor for AI-enabled medicinal chemistry workflows.
- Schrödinger: Physics-based computational chemistry and AI platform for molecular design. A direct competitor in enterprise pharma AI drug discovery, with a longer commercial track record and larger installed base.
- BullFrog AI: AI-driven drug discovery platform focused on improving clinical trial success rates through proprietary data networks. Another complementary platform at Sygnature Discovery alongside Dalton, with overlapping customer base in AI-enabled discovery.
- Insilico Medicine: AI-driven drug discovery company combining generative chemistry, target identification, and clinical development. Competes directly with DaltonTx in pharma-facing AI discovery platforms, though with a much larger funding base and proprietary pipeline.
- Exscientia: End-to-end AI-driven small molecule drug discovery company. DaltonTx's CEO, CTO, and CSO all previously built pioneering AI platforms at Exscientia, making it the most direct comparable in technology approach, customer base (pharma), and platform model.
- Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput biology with machine learning. Directly comparable in platform approach and pharma customer base, though focused on phenotypic screening and pooled-data model architecture.
Broad incumbents
- Benchling: Cloud-based R&D platform serving biotech customers with lab informatics, molecular biology, and registry capabilities. Comparable in serving biotech R&D teams but at a much broader, infrastructure-level layer rather than AI discovery.
Emerging players
- Antiverse: AI-driven antibody discovery platform using generative models. Comparable as a UK-headquartered, early-stage AI biologics discovery peer with overlapping biotech customer base, particularly for novel antibody and biologics programmes.
- Cradle Bio: AI platform for protein and biologics design. Comparable to DaltonTx's biologics discovery capability and overlapping customer base in biotech pursuing novel biologics, though with narrower modality focus.
- Isomorphic Labs: Alphabet-backed AI drug discovery company focused on applying DeepMind's AlphaFold-derived approaches. Comparable in long-term ambition to build AI foundations of pharma R&D, though backed by vastly greater resources and not yet at full commercial scale.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
DaltonTx social profiles
Digital presenceDaltonTx financial estimates
Financial estimateRevenue estimate
Valuation estimate
DaltonTx leadership team
Management profileNumber of profiles
Profiles4 records
DaltonTx funding detail
Funding detailFunding overview
Funding rounds1 record
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
DaltonTx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about DaltonTx
What does DaltonTx do?
DaltonTx offers the Dalton platform, an AI-powered drug discovery system that integrates agentic AI, human expertise, and experimental data into a continuous learning engine for small molecules and biologics. The platform covers the full discovery lifecycle including data ingestion, model training, molecule generation, synthesis planning, and experiment prioritisation. It links molecules, assays, models, experimental outcomes, project context, and human decisions into a single learning system that captures organisational memory across programmes.
Is DaltonTx a public or private company?
DaltonTx is a private company. It is classified as venture growth investor backed and is currently operating.
When was DaltonTx founded?
DaltonTx was founded in 2025. It employs 11 to 50 people.
Where is DaltonTx based?
DaltonTx is headquartered in London, United Kingdom, in the Europe region.
How does DaltonTx make money?
One revenue line is on record: platform Subscription/ Licensing.
Who are DaltonTx's main competitors?
Direct peers on record are Iktos, Schrödinger, BullFrog AI, Insilico Medicine, Exscientia and Recursion Pharmaceuticals. Benchling is listed as a broad incumbent. Emerging players are Antiverse, Cradle Bio and Isomorphic Labs.
Does DaltonTx have an API?
No public API is recorded for DaltonTx.
What industry is DaltonTx in?
DaltonTx's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 5132 and its SIC code is 7373.